이뮨온IMNN 주가

[4] 내부자 거래 — FORM 4

♻️ 재탕[4] 내부자 거래 — FORM 4

♻️ 재탕[4] 내부자 거래 — FORM 4

♻️ 재탕[4] 내부자 거래 — FORM 4

♻️ 재탕[4] 내부자 거래 — FORM 4

♻️ 재탕[4] 내부자 거래 — FORM 4

[SCHEDULE 13G/A] SCHEDULE 13G/A

IMNN: On Track to Have 80 Patients Enrolled in Phase 3 OVATION 3 Trial by 1Q27

By David Bautz, PhD NASDAQ: IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Fully Focused on Rapidly Advancing OVATION 3 Trial Imunon, Inc. (NASDAQ: IMNN) is currently conducting the Phase 3 OVATION 3 trial of IMNN-001 in women with newly diagnosed advanced ovarian cancer, and it remains the company’s top priority. The trial is designed to confirm the overall survival benefit observed in

Imunon Inc (IMNN) Q1 2026 Earnings Call Highlights: Promising Clinical Progress Amidst Funding ...

Imunon Inc (IMNN) reports strong advancements in its Ovation 3 study, despite facing a tough capital funding environment.

Imunon (IMNN) Q1 2026 Earnings Transcript

Stacy R. Lindborg: Thank you. During today's call, management will be making forward-looking statements regarding Immuneon's expectations and projections about future events. In general, forward-looking statements can be identified by words such as expects, anticipates, believes, or other similar expressions.